Risk adjusted net present value: What is the current valuation of Kymera Therapeutics’s KT-413?

KT-413 is a small molecule commercialized by Kymera Therapeutics, with a leading Phase I program in Primary CNS Lymphoma.

Unlocking the appetite-stimulating secrets of cannabis through rodent brain studies

Study reveals that cannabinoid-1 receptor-expressing neurons in the mediobasal hypothalamus play a key role in the appetite-stimulating effects of inhaled cannabis in rodents, offering insights

January 3, 2024

Early signs of inflammatory bowel disease detected in newborns

Across the Western world, the prevalence of these chronic and serious conditions, which have no cure, is rising. In Denmark alone, 50,000 people suffer from

October 12, 2024

Mental health problems may lead to obesity, other health problems for Latinx teens

Latinx kids who experienced depression, anxiety or other mental health issues in middle school had a greater chance of developing sleep problems, unhealthy weight gain

October 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.